# Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis

> **NCT01506362** · PHASE2 · COMPLETED · sponsor: **BioLineRx, Ltd.** · enrollment: 22 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** BL-7040

## Key facts

- **NCT ID:** NCT01506362
- **Lead sponsor:** BioLineRx, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01506362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01506362, "Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01506362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*